BELLEVILLE, ON,
June 13, 2014 /CNW/ - Bioniche Life
Sciences Inc. (TSX: BNC) - ("Bioniche" or the "Company"), a
clinical stage biotechnology company whose anchor product is a
Phase III treatment for non-muscle-invasive bladder cancer, today
announced that Dr. Michael Berendt,
Chief Executive Officer and Chief Scientist of Bioniche Life
Sciences Inc., will present a corporate update at the Bloom Burton
& Co. Healthcare Investor Conference at the Toronto Board of Trade on June 18, 2014 at 3:30 P.M.
EDT in Toronto.
Bioniche's corporate presentation will be available on the
Company's website at www.bioniche.com following the
presentation.
Bloom Burton's third annual healthcare investor
conference features Canada's
premier publicly-traded and venture-backed private companies. The
event will attract Canadian, U.S. and European investors who are
interested in the latest developments in Canadian healthcare
companies.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a clinical stage
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and
innovative therapies for the global human health market. The
Company's primary goal is to develop and commercialize products
that advance human health and increase shareholder value. For more
information, please visit www.Bioniche.com.
Except for historical information, this news
release may contain forward-looking statements that reflect the
Company's current expectation regarding future events. These
forward-looking statements involve risk and uncertainties, which
may cause, but are not limited to, changing market conditions, the
successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties
related to the regulatory approval process, and other risks
detailed from time to time in the Company's ongoing quarterly and
annual reporting.
SOURCE Bioniche Life Sciences Inc.